Biovision Ventures

Biovision Ventures focuses on pre-seed and seed-stage companies, often providing the first institutional capital. The firm's typical initial check size is estimated between €500,000 and €2 million, with reserves held for follow-on investments through later rounds.

The firm invests across human health, including biotech, medical devices, diagnostics, and AI-enabled drug discovery. It targets indications in oncology, neurology, and rare disease, where scientific complexity and regulatory hurdles create barriers that generalist investors rarely cross.

Biovision Ventures concentrates on Europe and Israel. Its diligence network draws on relationships with research institutions including ETH Zurich, Charité Berlin, and the Weizmann Institute, reflecting a focus on deep-science clusters rather than broad geographic coverage.

Biovision Ventures is structured as a private equity firm, not a single-family office. It raises capital from external limited partners and deploys it through a fund structure, though specific fund vintages and limited partners have not been publicly disclosed.

Yes — Biovision Venture has participated in syndicates with other European health-tech specialists and university-affiliated venture arms. The firm works alongside co-investors who bring complementary clinical or commercial expertise rather than competing for allocation in later-stage rounds.